Edwards Lifesciences

1. Liczba

   TAVR second quarter global sales reached $1.3 billion, an increase of 10.5% over the prior year, which were stronger than expected.

   Cytat ze źródła

   “TAVR second quarter global sales of $1.3 billion were stronger than expected and increased 10.5% over the prior year.”

2. Słabnie

   Adjusted gross profit margin was 78.3%, down slightly from 79% last year but in line with expectations.

   Cytat ze źródła

   “For the fourth quarter, our adjusted gross profit margin was 78.3%, in line with our expectations. And now I'll cover additional details of our P&L. Compared to 79% in the same period last year.”

3. Słabnie

   Annual sales grew by 10% with constant currency operating margin expansion as the company advanced novel therapies and maintained high single-digit procedural growth for TAVR.

   Cytat ze źródła

   “Now, I will provide an overview of Q4 sales performance by product group. ...annual sales growth of 10% with constant currency operating margin expansion as we continue to address patients in need by advancing novel therapies to extend lives, improve quality of life, and provide greater impact and efficiency for health systems. TAVR overall procedural growth in the quarter remained in the high single digit.”

Management sounded noticeably less positive answering analysts than in its prepared script — a bigger drop than in 85% of calls. Scripts are polished in advance; a drop under questioning often marks the topics analysts pressed on, so the answers deserve a closer read than the script.